On the Record · PTC Therapeutics

PTC Therapeutics acquisitions, on the record

The businesses PTC Therapeutics bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Complete Pharma Holdings, LLC (formerly Marathon Pharmaceuticals, LLC) Word for word“On April 20, 2017, we completed our acquisition of all rights to Emflaza, or the Emflaza Transaction.” 10-K for 2023	acquisition	April 20, 2017	—
BioElectron Technology Corporation Word for word“On October 25, 2019, we completed the acquisition of substantially all of the assets of BioElectron Technology Corporation, or BioElectron, pursuant to an Asset Purchase Agreement by and between the Company and BioElectron, dated October 1, 2019, or the BioElectron Asset Purchase Agreement.” 10-K for 2023	acquisition	October 25, 2019	—
Censa Pharmaceuticals, Inc. Word for word“In connection with our acquisition of Censa Pharmaceuticals, Inc., or Censa, in May 2020, we became a party to a license agreement dated as of February 8, 2015, as amended, between Shiratori and Censa, or the Shiratori License Agreement.” 10-K for 2023	acquisition	May 2020	—
Complete Pharma Holdings, LLC (formerly Marathon Pharmaceuticals, LLC) - Emflaza Word for word“On April 20, 2017, we completed our acquisition of all rights to Emflaza, or the Emflaza Transaction.” 10-K for 2024	acquisition	On April 20, 2017	—
Agilis Biotherapeutics, Inc. Word for word“On August 23, 2018, we completed our acquisition of Agilis pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018, or the Agilis Merger Agreement, by and among us, Agility Merger Sub, Inc., a Delaware corporation and our wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, or the Merger.” 10-K for 2024	acquisition	On August 23, 2018	—
BioElectron Technology Corporation - substantially all of the assets Word for word“On October 25, 2019, we completed the acquisition of substantially all of the assets of BioElectron Technology Corporation, or BioElectron, pursuant to an Asset Purchase Agreement by and between us and BioElectron, dated October 1, 2019, or the BioElectron Asset Purchase Agreement.” 10-K for 2024	acquisition	On October 25, 2019	—
Gene therapy manufacturing business in Hopewell Township, New Jersey Word for word“In June 2024, we sold our gene therapy manufacturing business in Hopewell Township, New Jersey.” 10-K for 2024	divestiture	In June 2024	—
Emflaza (Marathon Pharmaceuticals, LLC, now Complete Pharma Holdings, LLC) Word for word“On April 20, 2017, we completed our acquisition of all rights to Emflaza, or the Emflaza Transaction.” 10-K for 2025	acquisition	April 20, 2017	—

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)
2016-12-31	$0
2017-12-31	$0
2018-12-31	$48.9 million
2019-12-31	$0

Deal filings since 2016

2026-08-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-06-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-12-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-08-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-01-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-12-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-11-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-06-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-10-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-10-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-05-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-07-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-06-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-05-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-04-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-10-30 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2019-09-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-08-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-08-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-01-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-08-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-08-24 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2018-08-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-07-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-04-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-05-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-20 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-03-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from PTC Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.